Navigation Links
InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
Date:11/3/2011

BRISBANE, Calif., Nov. 3, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2011.  InterMune also highlighted its recent business and clinical development activities, including the launch of Esbriet® (pirfenidone) in Germany.  

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "The third quarter was highlighted by the launch of Esbriet in Germany at the Annual Congress of the European Respiratory Society in late September, which provided an outstanding forum to roll out the Esbriet launch campaign.  We are very pleased by the high level of awareness of and interest in Esbriet among German pulmonologists and the demand for Esbriet in Germany during the six weeks since launch is meeting our expectations.  Looking beyond Germany, our plans are on schedule to make Esbriet available to patients in additional countries in Europe and our Phase 3 study ASCEND is on track with our expectation to complete enrollment in the first half of next year."

Recent Clinical Development, Business Highlights and Upcoming Milestones  Esbriet® (pirfenidone):  

  • Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch Esbriet in France, Spain and Italy during the first half of 2012 and the United Kingdom in the third quarter of 2012.  InterMune also plans to launch Esbriet in substantially all of the Top 10 EU countries by the end of 2012.  
  • InterMune today reported that Austria is the third country in which InterMune has obtained a published price for Esbriet, in addition to Germany and Norway.
  • InterMune today reported that hundreds of patients have enrolled in the NPP across the EU countries, including Germany, and that it expects that virtually al
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. InterMune Announces Pricing of Concurrent Public Offerings of 4,000,000 Shares of Common Stock and $135 Million Principal Amount of Convertible Senior Notes
    2. InterMune to Release Second Quarter Financial Results on August 4
    3. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
    4. InterMune to Webcast 2011 Analyst Day Presentations
    5. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
    6. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
    7. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
    8. InterMune to Release First Quarter Financial Results on April 28
    9. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
    10. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
    11. InterMune to Release Third Quarter Financial Results on October 28
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Rockville, MD (PRWEB) January 23, 2015 ... delivers modern digital workplaces on Microsoft Office 365 and ... 2015 Future 50 Award program for being one of the ... of revenue and employee growth. , “To be recognized ...
    (Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
    (Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
    (Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
    Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
    ... 1 SynCo Bio Partners B.V., the,expert in long ... has expanded its business into a new geographical,market, with ... biotherapeutic,for an emerging Japanese pharmaceutical company. , ... live biotherapeutic,based anticancer drug. The project will first involve ...
    ... , , FORT LAUDERDALE, Fla., ... a leader in integrated electronic data capture (EDC) ... fastest growing companies in the EDC marketplace, announced today that ... have joined its rapidly expanding partnership program, the CRO Preferred ...
    ... , , SOUTH SAN FRANCISCO, ... changing the paradigm of drug discovery and development through the ... Plunkett, Ph.D., as vice president and chief financial officer. , ... term success, and Matt,s career over the last decade has given ...
    Cached Biology Technology:SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer 2
    (Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
    (Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
    (Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
    Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
    ... Conservation Society in an atoll reef lagoon in Glover,s ... encouraging increases in populations of predatory fish species. However, ... herbivorous fish, which feed on the algae that smother ... will help WCS researchers in their search for new ...
    ... Va. Battlefield corpsmen and medical professionals across the country ... and Drug Administration approved the first hand-held device to ... the unit, called the Infrascanner, was initiated and funded ... portable, battery-powered medical device reveals intracranial hematomas soon after ...
    ... -- Bioengineers at Tufts University School of Engineering ... deliver precise amounts of drugs over time and without ... under normal temperature and pressure and from water, so ... maintain their activity prior to use. They are also ...
    Cached Biology News:Belize protected area boosting predatory fish populations 2Belize protected area boosting predatory fish populations 3Naval technology could be a lifesaver 2Silk microneedles deliver controlled-release drugs painlessly 2
    Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
    Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
    Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
    MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
    Biology Products: